Archive 2022 2022 - 22 December 2022 -Year End Trading Update - 7 December 2022 – FDA/CDC highlight need for infection preventions - 7 December 2022 – XF-73 Nasal Phase 3 development plans finalised - Biotech Showcase conference – 9-11 January 2023 - 21 November 2022 – Destiny Pharma’s AMR Paper - 18 November 2022 – Dr Bill Love speaks to Proactive Investors about how Destiny Pharma is addressing the Global threat of superbugs and AMR - 15 November 2022 – XF-73 Dermal infection project advances into clinically enabling safety study with US Government’s NIAID - 14 November 2022 – New report highlights fast growing market for Live Biotherapeutics, Destiny Pharma’s NTCD-M3 is leading play in this sector - Inv€$tival Showcase – 14 November 2022 - Jefferies London Healthcare conference – 15-17 November 2022 - 19 October 2022 – Destiny Pharma R&D Investor Update meeting presentation recording - Microbiome Connect USA – 16-17 November 2022 - BIO-Europe 2022 – 24-26 October 2022 - 22 September 2022 – Notice of R&D Update Meeting - 08 September 2022 – Interim results for six months ended 30 June 2022 - 07 September 2022 – Destiny Pharma CEO, Neil Clark, to present at the HC Wainwright 24th Annual Global Investment Conference - 07 September 2022 – Positive update from European Medicine Agency (EMA) on NTCD-M3 Phase 3 development plans - HC Wainwright 24th Annual Global Investment Conference – 12-14 September 2022 - 22 August 2022 – Notice of Interim Results and Investor Presentation - 7th Microbiome Movement Drug Development 2022 – 21-24 June 2022 - Anaerobe 2022 – 28-31 July - 28 July 2022 – Chair’s Investor Update - 26 July 2022 – Publication of new data on NTCD-M3 - 19 July 2022 – Positive update from US FDA on XF-73 Phase 3 - ID Week – 19-23 October 2022 - 12 July 2022 – Destiny Pharma receives award from the Cystic Fibrosis Foundation - 07 July 2022 – Destiny Pharma announce publication of XF-73 drug synergy data - 05 July 2022 – Destiny Pharma announces start of a new XF-73 research programme - 8th Annual Microbiome Connect: Europe 2022 – 6-7 July 2022 - 7th Microbiome Movement Drug Development – 21-24 June 2022 - 27 May 2022 – Result of Annual General Meeting and Strategy Update - 26 May 2022 – Destiny Pharma plc Board changes - BIO International Convention – 13-16 June 2022 - 12 May 2022 – Landmark NTCD-M3 data to be presented at Anaerobe - Bio€quity Europe – 16-18 May 2022 - LSX World Congress 2022 – 10-11 May 2022 - 04 May 2022 – Destiny’s Chief Business Officer, Dr Stephanie Bewick, speaks to Labiotech about her role - 03 May 2022 – Destiny Pharma appoints Dr Yuri Martina as Chief Medical Officer - 27 April 2022 – Posting of Annual Report and Notice of AGM - World of Microbiome – 28-30 April 2022 - Infection Prevention and Control – 26-27 April 2022 - 12 April 2022 – Audited results for year ended 31 December 2021 - 31 March 2022 – Presenting data at the ECCMID 2022 Congress - 28 March 2022 – Result of the General Meeting held on 28 March 2022 - 28 March 2022 – Result of General Meeting and Total Voting Rights - 25 March 2022 – Result of Open Offer - 25 March 2022 – Destiny’s microbiome project article published in Vantage - 23 March 2022 – Destiny Pharma publish in the European Biopharmaceutical Review Journal “Global Rise in AMR Threatens Infection Armageddon” - 22 March 2022 – Exercise of Options and Total Voting Rights - ECCMID 2022 – 23-26 April 2022 - 17 March 2022 – Open Offer Application Form - 17 March 2022 – Open Offer Application Form - 17 March 2022 – Form of Proxy - 17 March 2022 – Form of Proxy - 09 March 2022 – Circular to shareholders - 09 March 2022 – Circular to shareholders - 08 March 2022 – Fundraising - 08 February 2022 – Positive feedback from EMA on XF-73 Nasal gel Phase 3 programme - 01 February 2022 – Positive data in XF-73 Dermal study with NIAID - BIO-Europe Spring 2022 – 28-30 March 2022 - 24 January 2022 – Clinical and commercial opportunity of NTCD-M3 - 21 January 2022 – Destiny Pharma Lancet Report - 17 January 2022 – Strategy/Company/Ops Update - HC Wainwright Bioconnect Conference – 10-13 January 2022 Archive 2022 2021 2020 & Prior
